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Abstract:  Hepatitis B virus (HBV) is a major cause of acute and chronic hepatitis in 
humans. As HBV itself is currently viewed as a non-cytopathic virus, the liver pathology 
associated with hepatitis B is mainly thought to be due to immune responses directed 
against HBV antigens. The outcome of HBV infection is the result of complex interactions 
between replicating HBV and the immune system. While the role of the adaptive immune 
response in the resolution of HBV infection is well understood, the contribution of innate 
immune mechanisms remains to be clearly defined. The innate immune system represents 
the first line of defense against viral infection, but its role has been difficult to analyze in 
humans due to late diagnosis of HBV infection. In this review, we discuss recent advances 
in the field of innate immunity to HBV infection. 
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1. Introduction 
The outcome of hepatitis B virus (HBV) infection, as well as the severity of HBV-induced liver 
disease, varies widely between patients. In approximately 95 % of adults, exposure to HBV leads to an 
acute infection that is rapidly resolved without long-term consequences, whereas the remaining 5% fail 
to control viral infection, leading to chronicity. The rate of chronicity of viral infection is dramatically 
higher in neonates born from infected mothers, suggesting that mature immunity is important to clear 
infection. Patients with chronic hepatitis B (CHB) are at increased risk of developing severe liver 
disease, including cirrhosis and hepatocellular carcinoma (Figure 1) [1,2]. As HBV is currently viewed 
as a non-cytopathic virus, HBV-associated liver damage is thought to be the consequence of a long 
lasting cytolytic immune response against infected hepatocytes [3,4]. 
Figure 1. Natural history of HBV infections. HCC, hepatocellular carcinoma; NK, natural 
killer cells; NKT, natural killer T cells. 
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Both innate and adaptive arms of the immune system are generally involved in responding to viral 
infection, with innate responses being important for control of viral replication and dissemination very 
early after infection, as well as for timely orchestration of virus-specific adaptive responses [5]. In the 
case of HBV, it has been clearly shown that the adaptive response is needed for efficient and persistent 
control of infection [3,4]. However, the role of innate immunity has been more difficult to analyze, as 
HBV infection is usually diagnosed several weeks after the onset of infection when viremia is already 
high; thus the role of innate immunity in defense against HBV remains controversial. 
The liver is composed of parenchymal cells, hepatocytes (approximately 80% of liver cells), and 
non-parenchymal cells (NPC), which comprise (in order of decreasing abundance) liver sinusoidal 
endothelial cells (LSEC), intrahepatic lymphocytes (including natural killer (NK) and natural killer T 
(NKT) cells), Kupffer cells (KC), biliary cells, hepatic stellate cells (HSCs), and resident dendritic 
cells (DCs). Due to the large number of  immune cells  present, the liver may be considered an 
immunological organ, with particular innate immune features, and is therefore thought to play an 
active role in the first line host defense against pathogens [6,7]. After sensing the presence of a virus, 
professional innate immune cells (i.e., KC, DCs, NK, NKT) produce cytokines and chemokines that Viruses 2010, 2                               
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have antiviral properties (e.g.,  IFN-α,  IFN-ß, IFN-λ,  TNF-α…)  or  that  are  meant  to  attract  and 
stimulate adaptive immune cells (e.g., IL-2, IL-6, IL-10…). Non-professional cells (i.e., LSECs, HSCs, 
hepatocytes) can also have immunoregulatory functions by secreting cytokines or chemokines in 
response to infection [8]. In general, infected cells can detect the presence of viral components or 
PAMPs (pathogen-associated molecular patterns) via cellular sensors or PRRs (pattern recognition 
receptors, such as Toll-like receptors [TLRs], RIG-like helicases [RLHs], or Nod-like  receptors 
[NLRs]) [9,10], and produce antiviral type-I interferons (IFN) IFN-α and IFN-ß, as well as other pro-
inflammatory cytokines (e.g.,  IL-1ß, IL-6…) [11-13]. TLRs recognize microbes either at the cell 
surface or on lysosome/endosome membranes, while pathogens that invade the cytosol are detected by 
cytoplasmic PRRs such as RLHs or NLRs [9,10]. Various TLRs are expressed in parenchymal and 
non-parenchymal cells of the liver [14]. Hepatocytes express mRNA for all TLRs [15,16], whereas 
KCs and HSCs express TLR4 and TLR2 [17,18]. In the case of lymphocytes, T and NK cells express 
TLR1, 2, 4, 5 and 9, whereas B cells express high levels of TLR1, 6, 7, 9 and 10 [19]. Dendritic cells 
can be of myeloid (mDC) or lymphoid (plasmacytoid, or pDC) origin, and represent an important 
component of innate immunity in the liver. Both recognize and present antigen to T cells but are 
distinct in their TLR expression and cytokine production profiles [19]. Plasmacytoid DCs express 
TLR7 and 9 and produce large amounts of IFN-α, whereas mDCs express TLR2, 3, 4 as well as 9 and 
produce pro-inflammatory cytokines and IFN-β but not IFN-α [19,20]. While virtually all liver cells 
types express RLRs [21], the pattern of expression of NLRs in hepatocytes is not known. 
Hepatitis B virus components that are sensed by hepatocytes and other liver cells are still unknown, 
but the putative PAMPs are highlighted in Figure 2.  
Figure 2. HBV life cycle and putative ‘pathogen associated molecular patterns’ (PAMPs). 
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The direct antiviral effect of type-I IFNs is exerted by a variety of effectors expressed from genes 
whose transcription is directly stimulated by IFNs, (i.e., IFN-stimulated genes (ISGs)) [11-13]. The 
indirect antiviral effect of type-I IFNs is due to their stimulatory effect on innate and adaptive immune 
cells [8]. HBV is currently viewed as a stealth virus that can establish itself efficiently by evading the 
innate arm of the immune system. However, it remains unclear whether HBV elicits an innate response 
in infected hepatocytes, while escaping professional innate immune cells. In this review we will 
reconsider the stealth virus concept in the context of contrary findings which suggest that an innate 
immune response is triggered and counteracted by HBV. 
2. HBV, a stealth virus that does not elicit innate immunity? 
A characteristic feature of acute HBV infection is a prolonged incubation period during which no 
apparent clinical symptoms or biochemical manifestations of liver injury are observed. Indeed HBV-
infected patients are almost universally diagnosed after the onset of clinical symptoms, which occur 10 
to 12 weeks after infection [22]. Studies performed with animal models, including the woodchuck 
model [23] and HBV-infected chimpanzees [24], have suggested that viral replication remains largely 
undetectable until 3-4 weeks post-infection, then “explodes” infecting almost all hepatocytes. These 
studies, together with studies performed with patient samples [3,4],  clearly establish the role of 
adaptive immunity for clearance of the virus after acute infection. In contrast, the potential role of 
innate responses has been difficult to analyze, because of the difficulty of finding a cohort of patients 
in the acute phase. The reasons for the delayed appearance of measurable levels of HBV proteins and 
DNA in the first weeks of infection are not clear. It has been suggested that immediately after 
infection,  HBV could be retained in other organs before reaching the liver,  as  described for the 
woodchuck hepatitis virus (WHV), for which the initial site of infection has been reported to be the 
bone marrow [25]. However this possibility is still speculative as the lymphotropism of WHV is more 
pronounced than that of HBV [25,26]. Another possibility is that HBV might initially infect very few 
hepatocytes, then spread very slowly throughout the liver. This lag phase, without measurable viremia, 
is difficult to study during human HBV infection. 
Using experimentally infected chimpanzees, microarray analyses have suggested that HBV, early in 
infection, does not modify host cellular gene transcription  and  does not  induce innate antiviral 
responses  in hepatocytes  and the liver [27]. In this study,  global gene expression profiling  was 
performed using liver RNA obtained at multiple time points after infection of three chimpanzees. All 
three infected chimpanzees developed a self-limited infection, reaching very similar viral titers and 
cleared the virus with relatively similar kinetics  profiles. The clearance of the virus was clearly 
associated with an efficient adaptive immune response. After establishing the gene expression profiles 
for all animals, genes with expression patterns correlated with the amount of HBV DNA in the liver of 
all three animals over the entire time course could not be identified. The failure of the virus to induce 
cellular gene expression as it spread through the liver suggested that HBV behaves as a stealth virus, 
capable of evading the first line of host defences [24]. HBV infection clearly contrasted with hepatitis 
C virus (HCV) infection in the same model; indeed, HCV infection is accompanied by a profound 
modification of cellular gene expression, in particular of ISGs. It was proposed that the invisibility of 
HBV to the innate sensing machinery of the cells could be partially attributable to its replication 
strategy. First of all, templates for HBV transcription are retained in the nucleus. Second, transcription Viruses 2010, 2                               
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of viral genes involves the production of capped and polyadenylated viral mRNAs that resemble the 
structure of normal cellular transcripts. And third, HBV sequesters its genome within viral capsid 
particles in the cytoplasm [28]. However, a role for the innate immune response in the control of early 
HBV replication should not be dismissed as the expression of the relevant genes might occur below the 
level of detection of the microarray analysis and/or in a limited number of cells at a given time point. 
Whether these observations can also be translated to the pathogenesis of natural human infection is still 
unknown. HBV hepatitis is generally milder in chimpanzees than in humans, and it is possible that the 
inability to detect activation of genes related to innate immunity reflects the milder disease 
manifestation.  
So far no gene expression analysis has been performed in the human setting during the acute phase. 
However, a  few studies have quantified circulating innate cytokines/chemokines and analysed the 
function of circulating NK/NKT cells in patients with acute HBV infection in order to measure the 
early kinetics of innate immunity. In a study reported by Stacey and collaborators, the immune 
response induced during the initial stages of infection was characterised by performing kinetic 
quantification of circulating innate cytokines/chemokines on plasma samples of 35 HIV, 10 HBV, as 
well as 10 HCV patients in the acute phase of infection [29]. This work showed striking differences in 
the pattern of elevation in cytokine and chemokine levels observed in plasma during the phase of 
exponential viral amplification. Indeed, a  strong and rapid induction of classic innate cytokines 
followed by multiple other cytokines was detected in acute HIV infection whereas weaker perturbation 
in plasma cytokine levels was observed in acute HBV infection. Cytokine levels after HCV infection 
were delayed and less intense compared to that observed in acute HIV infection, but more intense than 
that observed for HBV. Although weaker, the production of cytokines/chemokines after HBV infection 
was not null. Several HBV patients produced detectable levels of systemic IFN-α, TNF-α, IL-15,  
IL-10, IL-6, and/or IL-1β within 10 days after initiation of viral expansion and before the peak of 
viremia, suggesting that a significant innate response to HBV can be detected in some patients. In 
contrast, another recent study, performed on 21 HBV patients during the pre-symptomatic phase, 
showed that type-I IFNs, IL-15, and IFN-λ1 were not appropriately induced before or concomitantly 
with the peak of viremia, as compared to the systemic induction observed during hepatitis A virus 
(HAV) infection [30]. Interestingly, the level of serum  IFN/IL-15 was found to be lower at peak 
viremia than during the resolution of disease, suggesting that HBV  may be able to inhibit the 
production of these cytokines. In these same patients, The peak of viremia coincided with high levels 
of IL-10, an anti-inflammatory cytokine involved in the inhibition of NK and T-cell functions. 
Altogether the authors of this study concluded that the virus was not able to elicit a strong production 
IFN/IL-15 cytokines, but did induce the production of IL-10. They proposed that, in addition to failing 
to induce some immune mechanisms, HBV uses an immunosuppressive strategy to actively inhibit 
others [30].  
The results obtained in these HBV studies deserve some discussion. Since HBV replicates in the 
liver, in contrast to HIV which replicates mainly in PBMC, it is not surprising that cytokines produced 
by innate immune cells are not found at the systemic level. That HAV, another hepatotropic virus, does 
induce a systemic production of type-I IFN is not really informative,  as  HAV is not capable of 
inducing  chronic infection and may not have evolved successful strategies to counteract host 
immunity. Based on published literature, it seems that HBV induces a cytokine response that is more 
pronounced in humans than in chimpanzees. The production of cytokines in response to infection, Viruses 2010, 2                               
 
1399 
including IL-10, suggests that HBV can be detected in some way by the host. However, it will be 
difficult to address these questions in more detail, as the study of gene expression in serial liver biopsy 
specimens of patients experiencing an acute HBV infection will not be ethically feasible.  
As a characteristic of chronic infection, HBV appears to be able to induce a long-lasting inhibition 
of innate immunity. A recent clinical study investigated the immune mechanisms acting during the 
pathogenesis of spontaneous or antiviral withdrawal-induced hepatic flares (i.e., sudden changes of 
HBV viremia) in chronically infected patients. Signs of immune reactivation were almost completely 
absent during the rebound of HBV replication [31]. Serum levels of pro-inflammatory cytokines (IL-1, 
TNF-α,  IL-6 and IFN-α)  were  measured  and  were  consistently  normal.  Only  IFN-γ  inducible 
chemokines CXCL-9 and -10 were found increased in the serum of patients experiencing these hepatic 
flares. Although this study was performed in patients undergoing a reactivation of HBV replication 
(with titers increased from 10
2-3 to 10
9-10) and not during primary infection, the findings are consistent 
with the idea that HBV might escape innate immune recognition. However, it is worth noting that no 
quantification of HBsAg or HBeAg was reported during the observed flares. Since these molecules 
have putative immunomodulatory functions, including the inhibition of innate immune cells, it would 
have been interesting to follow their serum  levels  to  probe for possible mechanisms of immune 
evasion. 
To summarize, HBV, in contrast to HCV, does not seem to extensively modify gene expression in 
the liver during the acute phase and does not elicit a strong innate immune response, as evidenced by 
the low level of innate immune cytokines detected systemically (i.e., in serum). However, one cannot 
exclude the possibility that HBV induces a modest local modification of gene expression in immune 
cells or hepatocytes leading to the local production of innate immune cytokines, including cytokines 
with antiviral properties.  
3. Can HBV, as other viruses, be sensed by the immune system? 
A recent study performed in the woodchuck model showed that woodchuck hepatitis virus (WHV) 
could be detected by the innate immune system. Both natural killer and natural killer T cell responses 
could be mounted soon after infection (i.e., hours p.i.) with a high dose of virus [32]. These responses 
were at least partially capable of  limiting  viral propagation (i.e.,  causing  a transient reduction of 
viremia), but were not followed by a prompt adaptive T-cell response, which occurred with a delay of 
4 to 5 weeks. These results suggest that, despite a potential very early detection of the infection by the 
innate immune system, WHV  would be able to induce immune tolerance and delay the adaptive 
response. Therefore, rather than being silent, hepadnaviruses could very efficient counteract the innate 
immune response, thus preventing the secretion of cytokines during the early phases of infection. 
Somehow weakening these observations, it is worth noting that, in this study, high doses of virus were 
used for the inoculation of woodchucks (i.e.,  1.1x10
10), which clearly exceeds  a  physiological 
infectious dose. The two human studies described above showed i) that one patient had elevated levels 
of IL-15 and NK cell activation and function just before or at the peak viremia [30] and ii) that in 
approximately 50% of subjects a detectable level of systemic IFN-α, TNF-α, IL-15, IL-10, IL-6, and 
IL-1β could be detected within 10 days after initiation of viral expansion and before the peak of 
viremia [29], suggesting that the virus could be sensed by the innate immune system in those HBV 
infected patients.  Viruses 2010, 2                               
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Mice transgenic for replication-competent HBV genome expressed in their hepatocytes have been 
used to study the  antiviral effects of type I interferon [33]. Indeed, IFN-α  and  IFN-ß-induced 
responses, in this model, inhibited the formation of new HBV capsids, destabilized existing capsids, 
and degraded preformed HBV RNA [33]. Further indirect observations have also suggested that innate 
immunity could be important in the natural control of HBV replication. In HBV-transgenic mice 
deficient for IFNAR1, PKR or IRF1, which are components of the innate response, HBV replication 
was highly increased as compared to that observed in wild type HBV transgenic mice [34]. Recent 
genetic studies performed in humans  have also shown that polymorphisms in the ifnar1  gene 
correlated with an increased susceptibility to chronic hepatitis B (CHB) [35,36].  
In vitro, two main systems can be used to study HBV replication: primary human hepatocytes 
(PHH) [37] and cell lines of liver progenitor (i.e., HepaRG [38]). Using isolated PHH (with low level 
of contamination with non parenchymal cells, NPC) and NPC, Hösel et al. investigated whether and 
how HBV was detected by parenchymal and/or non parenchymal  cells and analyzed  downstream 
events [39]. It was shown that HBV was recognized by KC, although the virus does not replicate in 
these cells, and that within hours post infection, this recognition leads to the activation of NFκB and 
subsequently to the release of IL-6 and other pro-inflammatory cytokines (i.e., IL-8, TNFα, IL-1ß). 
Interestingly, in this experimental setting, no induction of type-I interferon (i.e., IFN-β) was observed. 
The activation of IL-6 and other pro-inflammatory cytokines was transient and inhibited 
responsiveness to a subsequent challenge. The IL-6 released by KC after the activation of NFκB was 
shown to control HBV gene transcription and replication in hepatocytes shortly after infection. 
Mechanistic analysis revealed that IL-6 activated the mitogen-activated protein kinases ERK1/2 and 
JNK, which in turn inhibited the expression of hepatocyte nuclear factor (HNF) 1α and HNF 4α, two 
transcription factors essential for HBV gene expression and replication [39]. It was suggested that IL-6 
could ensure an early control of virus replication, thereby limiting the activation of the adaptive 
immune response and preventing death of the HBV-infected hepatocytes in the early phase of 
infection. This hypothesis fits well with the already described protective effect of IL-6 in the context of 
liver failure [40]. Alternatively, the production of IL-6 could be the hallmark of a tentative attempt by 
the host to inhibit HBV replication and clear viral infection. Interestingly, the production of IL-6 and 
other cytokines seems transient after HBV infection, and HBV replication tends to increase after 3-4 
days post infection when IL-6 level has already returned to baseline. This suggests that the virus 
actively counteracts the effects of IL-6. Hence, like the human cytomegalovirus [41], HBV may have 
evolved mechanisms to modulate the expression or signaling of IL-6 as part of the viral arsenal of 
immune evasion strategies.  
It is somewhat surprising that HBV does not seem to induce the production of type-I IFN in infected 
primary human liver cells, as this cytokine is frequently produced and secreted by cells infected by 
viruses  [11-13]. Interestingly, during the initial phase after viral entry, there appears to be a temporary 
block of HBV replication and spread  [42]. It remains possible that this is partially mediated by innate 
immune mechanisms. Hösel et al. have obtained results suggesting that the transcription of the IFN-β 
gene is not induced by HBV infection in PHH and/or KCs  [39]. It is worth noting that in PHH, as well 
as in HepaRG cells, the overall replication level is rather low, with approximately  20% of cells 
infected (as detected by immunostaining), which complicates the study of the  host/pathogen 
interaction  [37,38]. One could hypothesize that the low level of replication might be the consequence 
of an innate cellular response. In this case, the virus would trigger a host antiviral response that would Viruses 2010, 2                               
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limit HBV replication to only a low percentage of cells. This low percentage of infected cells is an 
obstacle for studying the potential ability of HBV to elicit a type-I IFN response. Indeed, in other viral 
models, when a low multiplicity of infection is used, which is likely the case during natural infection 
by HBV, it has been documented that an IFN response may occur in only a low percentage (<30%) of 
infected cells   [43]. Moreover, some viruses are particularly efficient at counteracting this IFN 
response and may therefore render the analysis of IFN response more difficult  [44]. This could be the 
case for HBV which has been shown to be very efficient at inhibiting the IFN signalling pathway   
[45-47]. Another technical obstacle for studying the potential ability of HBV to elicit an IFN response 
is that an inoculation time of 12-16 hours is required to  initiate a strong infection of cultured 
hepatocytes  in vitro. This is not compatible with the very early post-infection and synchronized 
analysis that would likely be necessary to detect a potentially weak and transient IFN response. To test 
the hypothesis that HBV can elicit and then disarm a type-I IFN response in cell culture, it seemed 
necessary to initiate time-controlled and high-level HBV replication in a large number of cells. Hence, 
Lucifora et al., performed a study in HepaRG cells replicating HBV at high level after transduction of 
the cells by a recombinant baculovirus carrying the whole HBV genome (i.e., Bac-HBV)  [48]. It was 
shown that hepatocytes, in the absence of NPC, can mount an innate antiviral response which results in 
a non-cytopathic clearance of HBV DNA [49]. Cellular gene expression analyses showed that IFN-ß 
and other interferon stimulated genes were up-regulated in HepaRG cells transduced with Bac-HBV, 
but not in cells transduced by control baculovirus. Confirming the role of IFN-ß, viral replication was 
rescued when IFN-ß action was inhibited either by neutralizing antibodies or RNA interference 
targeting the type-I IFN receptor. This baculoviral expression system showed that HBV replication 
could elicit a type-I IFN response in infected cells. This model utilizes overexpression of HBV, so the 
results need to be confirmed under more physiological conditions. The demonstration of very early 
virus-host cell interactions has been hampered by the lack of a powerful infection system based on 
physiologically relevant cells. 
A very recent study described innate and adaptive human responses in vivo in the incubation phase 
of HBV [50]. This study, performed on two seronegative blood donors who became HBsAg and HBV 
DNA positive without elevation of ALT and who were monitored at very early stage of infection, 
clearly established that the human innate immune system is also able to sense HBV infection and 
develop  NK  and  NKT  cell responses [50]. These observations are consistent with a  previous 
longitudinal analysis of circulating NK cells showing that their frequency is elevated in the incubation 
period of natural HBV infection with a subsequent decline at the time of the decrease in HBV 
DNA [22].  
Altogether, data reported with animal models or in vitro suggest that HBV can be sensed by the 
immune system early in infection and this response could be important for controlling HBV replication 
(Figure 3). The recently observed induction of cytokine and NK/NKT cell responses in humans 
suggests that, rather than being silent, HBV would be able to induce and counteract the action of the 
immune system.  Viruses 2010, 2                               
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Figure 3. Overview of early events after HBV infection. 1. Infection step (direct or via 
liver sinusoidal endothelial (LSEC) or Kupffer (KC) cells taking up and presentation). 2. 
Recognition step by toll like (TLRs), RIG-like (RLRs) or Nod-like (NLRs) receptors. 3. 
Direct antiviral action of produced cytokines. 3bis. Cell protection against infection. 4. 
Cross talk with specialized cells. BC, Bile caniculus; SD, Space of Dissé. 
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4. Can HBV inhibit type-I interferon pathways?  
Only approximately one third of patients with CHB respond to IFN-α  treatment. The cause of 
treatment failure in non-responders is not fully understood, but the interference of HBV with IFN-α-
induced JAK–STAT signaling has emerged as a possible escape strategy of HBV contributing to viral 
persistence and disease progression [45]. Several studies have reported HBV interference with IFN 
signaling pathways in vitro, using overexpression and/or non replicating systems, providing interesting 
insights about the molecular mechanisms used by HBV to counteract the effects of IFN. Most of these 
data, however, need to be confirmed in vivo. The first experimental evidence that HBV can interfere 
with IFN pathways came in the late 80’s to early 90’s. Twu and colleagues reported that HBV was able 
to inhibit the transcription of the ifn-ß gene in hepatoma cells [51], and identified the core protein as 
the main viral determinant of this inhibition [52]. Later, other groups also highlighted the involvement 
of HBV core protein in the inhibition of the IFN pathway. It was shown that the MxA protein, an 
effector of the IFN response, is totally inhibited in the HBV-replicating HepG2.2.15 cell line [46,53], 
in peripheral blood mononuclear cells (PBMC) from HBV chronically infected patients [54], as well as 
in HepG2 cells transfected with a re-circularized HBV DNA [46]. Moreover, co-transfection of an 
MxA promoter-driven reporter construct with an HBV core protein construct demonstrated, upon IFN 
induction, a clear inhibition of MxA expression [46]. This inhibition was due to a direct binding of the Viruses 2010, 2                               
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core protein with the ISRE sequence of the human MxA promoter [46]. Similar results were obtained 
in cells transfected with defective HBV genome. Defective HBV particles originating from the 
encapsidation of spliced HBV RNA are detected in the serum of hepatitis  patients, and more 
abundantly in patients with acute hepatitis progressing to CHB or with established CHB, as compared 
to recovering patients [55,56]. This suggests a potential role for the establishment of chronicity. In 
vitro, it was demonstrated that the expression of HBV DNA leads to a cytoplasmic accumulation of the 
core protein  which strongly reduces the antiviral activity of IFN-α  via  the  inhibition  of  MxA 
expression  [47].  
Beside core, other  HBV proteins have been  implicated in the inhibition of IFN pathway. For 
instance, it was shown that cells transfected by the terminal protein domain of the HBV viral 
polymerase are resistant to IFN-α, IFN-γ and dsRNA stimulation [57]. Furthermore, the expression of 
the terminal protein in the liver of infected patients is associated with a failure of hepatocytes to 
respond to interferon [58]. It is worth noting, however, that later in vitro  experiments failed to 
reproduce these observations, thus further investigation is warranted [59]. However, a recent study 
demonstrates that the HBV polymerase, and especially the terminal protein domain, inhibits the 
expression of the IFN-α-inducible protein MyD88 by interfering with target promoter activity through 
blockage of Stat1 nuclear import. Moreover, transcriptional activity of the ISRE promoter and 
expression of ISGs such as STAT1 and ISG15 were also inhibited [60]. HBV S and/or X proteins also 
seem to be involved in the inhibition of the IFN pathway. Indeed, using a cell line that allows the 
controlled expression of HBV and liver biopsies from patients chronically infected by HBV, it has 
been shown that HBV, and in particular S and/or X proteins, could also block STAT1 nuclear import 
by up-regulation of a cellular protein named pp2AC [45]. Similar results were previously reported by 
the same group using liver extracts from HCV transgenic mice and patients with CHC [61]. It has also 
been demonstrated that HBs antigens may affect the function of monocytes through inhibition of the 
NFκB and ERK pathway  [62]. Altogether, these data demonstrate that various HBV proteins can 
counteract the innate immune response by inhibiting different components  of the IFN signaling 
pathway (Figure 4). As most of these data were generated in vitro and not in the context of a proper 
infection, the relevance of these observations still needs to be analyzed in a more physiologic setting.  
5. Can HBV inhibit host sensors of the innate response?  
Beside  the inhibition of the downstream IFN signaling pathways, there is  a growing body of 
evidence suggesting that HBV can also interfere with the host recognition systems (Figure 4). Upon 
recognition of PAMPs, and as mentioned before, PRRs induce the production of IFN and other 
cytokines of the innate immune response and are therefore major players in the innate response [63]. 
Recently, interesting data have been generated showing that HBV can modulate the expression of 
TLRs and/or inhibit TLR signaling cascades, suggesting that HBV might use this strategy to escape the 
innate immune response. A downregulation of TLR-2 expression in PBMCs, as well as in KCs and 
hepatocytes from HBeAg positive patients was recently described [64]. This downregulation was 
associated with HBeAg positivity, which suggests an immunomodulatory role for this secreted viral 
protein. Interestingly in the HBV transgenic mouse model the only TLR ligand that did not induce an 
anti-HBV effect was the TLR-2 ligand [65]. This result could be explained by the HBV-induced 
downregulation of this receptor. This finding was confirmed and extended by recent data showing that Viruses 2010, 2                               
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PBMCs from patients with CHB expressed significantly lower levels of TLR-1, TLR-2, TLR-4 and 
TLR-6 mRNA compared to those from healthy donors  [66]. Moreover the production of cytokines in 
response to both TLR2 and TLR4 ligands by PBMCs from CHB patients was inhibited and there was a 
correlation between this inhibition and the level of HBsAg [66]. Finally, using the HBV transgenic 
mouse model, it was also demonstrated that HBV (either purified virions, HBeAg or HBsAg) 
suppresses the innate response elicited by TLR3 and TLR4 stimulation of hepatocytes and non 
parenchymal liver cells [67]. This correlated with the suppression of IFN-β production and subsequent 
decrease in the activation of interferon-stimulated genes (e.g., MxA, IP-10, NFκB, or pERK) [67]. 
Figure 4. Inhibition of host sensors and IFN pathway by HBV. 
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Amongst PBMCs, pDCs are the major type-I interferon producing cells and a key sensor of viral 
infections as they express both TLR7 and TLR9, TLRs that recognise, even in absence of viral 
replication, ssRNA and unmethylated CpG motifs, respectively [68]. A recent study has reported a 
reduction of TLR9 expression in pDCs of patients with CHB, which correlated with impaired IFN-α 
production [69]. Another study, this one using monocyte-derived dendritic cells (MoDCs) from CHB, 
analyzed the involvement of TLR3 in HBV infection and demonstrated that TLR3 was downregulated 
markedly in MoDCs from these patients [70]. Furthermore, the production of IFN-ß, a downstream 
cytokine of TLR3 signalling, was also reduced in MoDCs from CHB patients [70]. Altogether, these 
data suggest that HBV could alter the innate immune response triggered by both specialized cells and 
hepatocytes by inhibiting TLR functions, which may contribute to the establishment of chronic 
infections. However, other studies reported minor alterations of DC functions during CHB [71,72]. 
HBV-specific CD4
+ and CD8
+ T cells become detectable a short time after the exponential increase in 
HBV replication [22], suggesting that DC function is not affected by the virus at early phases of self-
limited HBV infection. These discrepancies might reflect differences between experimental model 
systems, particularly in the case of the  generation of DC from monocytic precursors. During 
preparation, artifacts may occur resulting in a cell population containing DC and non-DC; therefore, Viruses 2010, 2                               
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these studies have to be interpreted with caution. Also, whether these data are applicable to DC 
subpopulations in vivo still needs to be determined.  
Altogether, these data demonstrate that HBV proteins can counteract the innate immune response 
by inhibiting sensors, mediators, as well as effectors of the cellular antiviral innate response in vitro. 
One may hypothesize that HBV has evolved these mechanisms in its encounters with this type of 
response during its viral cycle in vivo. 
6. Concluding remarks  
In most immunocompetent adults, an acute HBV infection is resolved by an efficient adaptive 
immune response. Usually innate immune responses are necessary to mount a rapid and efficient 
adaptive immune response. In the case of HBV, the study of the role of the innate immunity has been 
complicated by the fact that patients are usually diagnosed long after the onset of infection. 
It is difficult to imagine that HBV would not elicit any innate immune response at all. However, 
HBV is generally believed to be a stealth virus that does not modulate host cellular gene transcription 
and does not induce an innate immune response when spreading throughout the liver. The available 
data suggest three possibilities: i) HBV originally evolved to evade innate immunity by not inducing it; 
ii) an innate immune response is elicited by HBV, as by other viruses, but at a lower extent and is 
therefore difficult to detect at the level of the liver sinusoid (local events); or iii) HBV induces an 
innate immune response but is rapidly capable to inhibit it. Such early events are difficult to analyze 
during natural infection in humans. However, recent in vitro and in vivo observations provide new 
pieces of evidence suggesting that HBV could be sensed by the immune system in humans during 
early infection and in animal models. The liver cells, including non-parenchymal  cells  and 
hepatocytes, might be able to sense HBV infection and mount an antiviral response, notably via an 
interferon response. The sensitivity of HBV replication to interferon has clearly been demonstrated in 
vitro  and  in vivo. This immune response may lead to epigenetic regulation of the transcriptional 
activity of the HBV covalently-closed-circular DNA or to other transcriptional or translational effects 
leading to the downregulation of viral gene expression and replication. Alternatively, in order to 
establish a chronic infection, HBV may evade this innate response or downregulate antiviral pathways, 
such as the interferon pathway, thus explaining some of the apparently contradictory results published 
in the literature. The experimental conditions, timing, and types of analyses are major variables that 
may have contributed to the controversy. Since all these findings may have major clinical implications 
for the immunological control of viral infection, more studies are warranted in relevant study models 
to better characterize the innate sensors detecting HBV, the innate effectors induced by HBV, the viral 
determinants  inducing the innate  response, and the mechanisms employed by HBV  to counteract 
cellular responses in order to establish persistent infection and resistance  to exogenous IFNα 
administration.  
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